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and communication they enable. We will also look at the practicalities of each
method, and their relative merits and drawbacks and how these can be addressed
to maximise their usefulness in refining and improving the translation.
CONCLUSIONS: We will argue that both methods are beneficial in particular cir-
cumstances, and will explore the situations in which each one would be the most
appropriate.
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WHAT EPRO MODALITY IS APPROPRIATE FOR YOUR STUDY?
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OBJECTIVES: To help clarify which ePRO modality (IVR, IWR, Handheld) is appro-
priate for specific studies through providing three examples of diary requirements
and appropriate modalities. Emphasize making this decision early in the planning
process.METHODS: Examples for three scenarios requiring patients to record their
PRO data electronically were drawn up based on experience to illustrate how mak-
ing appropriate modality choices can minimize patient burden and reduce costs.
Scenario One - 10,000 patient global vaccine study. Scenario Two – 500 patient
global study, daily diary having 40 questions with more than 5 response options.
Scenario Three – 50 GI patients to record their PRO data episodically using a VAS
scale daily for over a year. RESULTS: Scenario One – Appropriate Choice IVR: It is
expensive and logistically challenging for Sponsors to deploy 10,000 PDAs. Using
the IVR global network in place would reduce cost and logistics for the Sponsor and
sites. Scenario Two – Appropriate Choice IWR: When patients are provided more
than 5 response options in a lengthy questionnaire, an IWR would be better since
response options are visual. IWR would be better than PDA given the sample size
and logistics. Scenario Three- Appropriate Choice  PDA: A PDA would be most
convenient for the patient since they are providing data daily for over a year. PDA
is best for VAS scales since the size of the screen can be controlled. CONCLUSIONS:
There is overlap in deciding which ePRO modality to use for a particular clinical
study. It is critical to decide on the modality early when assembling the protocol, so
all points can be considered. Looking at the diary requirements (frequency, length,
access) for the study will help the Sponsor to decide which modality is best. Reduc-
ing patient and site burden will allow for greater compliance.
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OBJECTIVES: Attaining good patient health outcomes is the underlying purpose of
any health care intervention, including drug therapy. METHODS: The outcome
measure is the basis for evaluating the quality of health services, and a key element
in determining the value of health interventions since the value of health care is
defined as outcomes relative to cost. According to Porter (2010), value improvement
starts with defining and measuring the total set of outcomes for a medical condi-
tion and determining the major risk factors. Porter has provided a challenging
framework for identifying the full set of outcomes for any medical condition: the
outcome measures hierarchy (OMH). RESULTS:According to the OMH the full set of
outcomes for any medical condition, and its treatment, can be conveyed in a three-
tiered hierarchy. Each tier of the hierarchy contains two broad levels, each of which
involves one or more distinct outcome dimensions. Each medical condition should
have its own outcome measures. Measurement efforts should begin with at least
one outcome dimension at each tier, and ideally at each level. Possible outcome
dimensions for Attention-Deficit Hyperactivity Disorder (ADHD) are explored and
discussed according to Porter’s OMH. ADHD is a frequent neurobehavioral disorder
that is characterised by inattention, hyperactivity and impulsivity. ADHD is asso-
ciated with considerable social, family, behavioural and cognitive dysfunction, and
is comorbid to depression, bipolar disorder, anxiety, and drug use. Specific dimen-
sions proposed are aimed at capturing particular aspects of patients affected by
ADHD. For each dimension, success is measured with several clinical and patient
reported metrics. Tier 1 of the OMH is the patient’s health status achieved or
retained after a health intervention (clinical or drug therapy). CONCLUSIONS: Tier
2 regards the process of recovery and the eventual disutility of the treatment pro-
cess. Tier 3 concerns the sustainability of health.
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MEASURING RELATIVE EFFECTIVENESS IN EUROPE: AS IN THE USA, HERE TOO,
IT IS TIME TO TURN THE QALY PAGE
Prieto L
European Medicines Agency, London, UK
OBJECTIVES: The recently enacted Patient Protection and Affordable Care Act in
the United States of America (USA) has created a Patient-Centered Outcomes Re-
search Institute to conduct comparative effectiveness research, but has prohibited
this institute from developing or using cost-per-QALY thresholds. METHODS: In
reaction to this new legislation some authors, from both continents, have insisted
that QALYs provide a convenient yardstick for measuring and comparing health
outcomes of varied interventions across diverse diseases and conditions. Such
arguments in defense of QALYs are erroneous. While it is true that QALYs are
internationally recognized as the standard metric of the value of health outcomes,
this acknowledgement is, unfortunately, not deserved. RESULTS: The problem lies
in the QALY calculation (i.e. Utility x Time). While Time is expressed in a ratio scale
with a non-arbitrary zero value, Utility is defined as an interval scale with an
arbitrary zero point (i.e. death). Permissible arithmetic operations on interval
scales are limited: addition and subtraction are allowed, but multiplication and
division are not permitted because the absence of an absolute zero. Consequently,
the resulting QALY values are not expressed in the same units as the Time scale,
preventing any meaningful conclusion on its application to comparative clinical
effectiveness research. CONCLUSIONS: Although we do not know the exact rea-
sons why the Patient Protection and Affordable Care Act bans the use of cost per
QALY in the USA, the initiative should be celebrated, not criticized, and certainly
copied in Europe as well.
Cancer – Clinical Outcomes Studies
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OBJECTIVES: To assess the burden of hospitalization in advanced lung cancer pa-
tients in France and Germany. METHODS: Oncologists (N80) and pulmonologists
(N40) actively involved in management of Non small cell lung cancer (NSCLC) in
France and Germany were invited to participate in a lung cancer disease specific
program. Each consenting physician was asked to complete patient record forms
for the next 10 advanced (stage IIIB/IV) lung cancer patients seen in their practice.
The study period extended from July to October 2010. Data on hospitalization over
the past year was provided by the physicians using the patient chart records. The
primary reason of hospitalization and the length of stay (LOS) were reported.
RESULTS: Majority of the patients (N1213) were male (68%), Caucasian (92%),
Stage IV (89%), currently on first line therapy (51%) with an average age of 63 years.
Hospitalization records were obtained for 93% (n1133) of the patients among
which 30% (n341) of the patients had one or more hospitalization events in the
previous year with an average (SD) LOS of 10 (8) days. The primary cause reported
for the 449 hospitalization events were disease symptoms (44%), surgery (20%) and
therapy side effects (17%). The LOS for surgery related hospitalization (n89)
ranged from 1-20 days (mean: 8 days). Among patients hospitalized for disease
symptoms (n197) the most frequently reported primary causes were dyspnea
(23%), cough (10%) and pain (11%) with average LOS of 13, 12 and 8 days respec-
tively. Among patients hospitalized for side effects (n75), anemia (24%), febrile
neutropenia (8%), febrile aplasia (8%) were most frequently reported with average
LOS of 4 days. CONCLUSIONS: Burden of hospitalization due to disease symptoms
and treatment related side effects is significant in France and Germany. Innovative
therapies effective in alleviation of symptoms and side effects could help signifi-
cantly in decreasing hospitalization costs.
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OBJECTIVES: Unresectable metastatic melanoma patients (stages IIIc/IV) have a
poor prognosis. Recent improvements in survival have been attributed in part to
earlier detection and investigational therapies, however melanoma is considered
incurable if it becomes metastatic. No information about treatment patterns for
unresectable melanoma in Canada has been published. Objectives of this study
were to describe disease characteristics, treatment patterns, health outcomes, and
resource utilization for Canadian unresectable melanoma patients treated outside
randomized clinical trials [RCT]. METHODS: Charts of melanoma patients at seven
Canadian centres were screened for eligibility. Unresectable melanoma charts
then selected consecutively in reverse chronological order from January 2009 until
target number (n250) exceeded. Data on patient and disease characteristics,
treatments (across three lines), adverse event management, health outcomes and
resource utilization were then extracted from charts of patients with at least two
months of follow-up, from diagnosis until censoring (June 2010 or death). RESULTS:
Of 1426 melanoma patient charts reviewed, 262 (18%) were for unresectable mela-
noma patients, 16% (43/262) of which were first diagnosed in an advanced stage.
Overall, 10% (26/262) participated in an RCT during the follow-up period and 60%
(156/262) received systemic therapy outside an RCT. In the latter group, responsive-
ness to therapy was low; only 20% (26/132) on first-line and 16% (9/58) on second-
line therapy experienced complete or partial response. On first-line therapy, 40%
(53/132) experienced adverse events requiring medical management and 18% (24/
132) were hospitalized during treatment; corresponding figures for second-line
were 38% (22/58) and 24% (14/58) respectively. CONCLUSIONS: This study charac-
terizes treatment patterns and provides quantitative estimates of resource utiliza-
tion for unresectable melanoma patients across Canada. Extant systemic treat-
ments are associated with poor response and considerable resource utilization.
This study quantifies the grim prognosis faced by advanced melanoma patients in
Canada receiving currently available treatments.
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CETUXIMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL
CANCER
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OBJECTIVES: To evaluate the efficacy and safety of cetuximab in combination with
chemotherapy vs. chemotherapy alone for the first-line treatment of metastatic
colorectal cancer (mCRC), in patients with KRAS wild-type tumours. METHODS:
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